4. (Amended) A compound having the general structure:



wherein R_1, R_7 and R_8 are independently selected from the group consisting of H, halo, haloalkyl and hydroxy; and

R_3 is hydroxy or -$OCONH_2$[, with the proviso that at least one of R_1, R_7 and R_8 is other than H].

5. (Amended) The compound of claim 4 wherein R_7 and R_8 are H;

R_1 is H or F; and

R_3 is hydroxy or -$OCONH_2$.

6. (Amended) A method for treating a patient suffering from a neurological disorder, said method comprising the step of administering a composition comprising a compound [selected from the group consisting of] represented by the formula



wherein [R_1,] R_7, R_8 and R_9 are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy; and

R_3 is hydroxy or -$OCONH_2$[; and

R_4 is hydroxy or carbonyl, with the proviso that when R_9 is H, R_7 and R_8 are not both H].

7. (Amended) The method of claim 6 wherein said compound has the general structure



wherein [R_1] R_9 is selected from the group consisting of H, halo, haloalkyl and hydroxy; and

R_3 is hydroxy or -$OCONH_2$.

8. (Amended) The method of claim 7 wherein [R_1] R_9 is H or halo; and

R_3 is -$OCONH_2$.

A

9. (Amended) A method for preventing or limiting tissue damage resulting from an ischemic event [treating a patient suffering from tissue damage resulting from localized hypoxic conditions], said method comprising the step of administering a composition comprising a compound selected from the group consisting of



wherein [R_1,] R_7, R_8 and R_9 are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy; and

R_3 is hydroxy or -$OCONH_2$[; and

R_4 is hydroxy or carbonyl, with the proviso that when R_9 is H, R_7 and R_8 are not both H.].

A

10. (Amended) The method of claim 9 wherein said compound has the general structure



wherein [R_1] R_9 is selected from the group consisting of H, halo, haloalkyl and hydroxy; and

R_3 is hydroxy or -$OCONH_2$.

11. (Amended) The method of claim 10 wherein [R_1] R_9 is H or halo; and

R_3 is -$OCONH_2$.

12. (Amended) The method of claim 9 wherein the [localized hypoxic condition] tissue damage is caused by cerebral ischemia.

13. (Amended) The method of claim 9 wherein the [localized hypoxic condition] tissue damage is caused by myocardial ischemia.

A

~~14~~ 11. (Amended) A pharmaceutical composition comprising a compound selected from the group consisting of



wherein [R_1,] R_7, R_8 and R_9 are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;

R_3 is hydroxy or -$OCONH_2$; and

[R_4 is hydroxy or carbonyl, with the proviso that when R_9 is H, R_7 and R_8 are not both H; and]

a pharmaceutically acceptable carrier[,].

~~15~~ 12. (Amended) The composition of claim ~~14~~ 11 wherein said compound has the general structure

A



wherein [R_1] $\underline{R_9}$ is selected from the group consisting of H, halo, haloalkyl and hydroxy; and

R_3 is hydroxy or -$OCONH_2$.

13
~~16.~~ (Amended) The composition of claim 15 wherein [R_1] $\underline{R_9}$ is [selected from the group consisting of] halo[, haloalkyl and hydroxy].

17. (Amended) The composition of claim 15 wherein [R_1] $\underline{R_9}$ is H $\underline{\text{or F}}$; and

R_3 is -$OCONH_2$.

Please add new claims 18-27 as follows:

18. The composition of claim 15 wherein R_9 is H or F; and

R_3 is hydroxy.

A

19. A compound having the general structure:



wherein R_1, R_7, R_8, R_9 and R_{10} are independently selected from the group consisting of H, halo, alkyl, haloalkyl, $-NR_5R_6$, hydroxy, and alkoxy;

R_2 is F or Cl;

R_3 is hydroxy or $-OCONH_2$; and

R_5 and R_6 are independently C_1-C_4 alkyl.

20. The compound of claim 19 wherein

R_1 and R_7 are independently selected from the group consisting of H, halo, alkyl, haloalkyl, and hydroxy;

R_2 is F;

R_3 is hydroxy or $-OCONH_2$; and

R_8, R_9 and R_{10} are H.

21. The compound of claim 19 wherein

R_1 and R_8 are independently selected from the group consisting of H, halo, alkyl, haloalkyl, and hydroxy;

R_2 is F;

R_3 is hydroxy or $-OCONH_2$; and

R_7, R_9 and R_{10} are H.

22. The compound of claim 19 wherein

R_1 is selected from the group consisting of H, halo, alkyl, haloalkyl, and hydroxy;

R_2 is F;

R_3 is hydroxy or $-OCONH_2$; and

R_7, R_8, R_9 and R_{10} are H.

A

23. The compound of claim 22 wherein

R_1 is selected from the group consisting of H, F, Cl, CF_3 and hydroxy.

24. The compound of claim 23 wherein

R_1 is F.

25. A pharmaceutical composition comprising the compound of claim 19 and a pharmaceutically acceptable carrier.

26. A pharmaceutical composition comprising the compound of claim 22 and a pharmaceutically acceptable carrier.

27. A method for reducing the incidence and severity of an epileptic seizure in an individual, said method comprising the step of administering to said individual a compound represented by the general structure:



wherein R_1, R_7 and R_8 are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy; and

R_3 is hydroxy or $-OCONH_2$.

28. The method of claim 27 wherein R_1 is H or F, and R_7 and R_8 are H.

29. The method of claim 28 wherein R_3 is $-OCONH_2$.

A